Single Nucleotide Polymorphisms in Runt-related Transcription Factor 2 and Bone Morphogenetic Protein 2 Impact on Their Maxillary and Mandibular Gene Expression in Different Craniofacial Patterns - A Comparative Study

Bernardo Olsson, Mateus José da Silva, Camila Lago¹, Robson Diego Calixto, Lucas Alexandre Ramazzotto², Nelson Luis Barbosa Rebellato, Christian Kirschneck³, Francisco Wanderley Garcia Paula-Silva², Erika Calvano Küchler^{3,2}, Rafaela Scariot

Department of Stomatology, Federal University of Paraná, ¹Department of Oral and Maxillofacial Surgery, School of Health Sciences, Positivo University, Curitiba, ²Department of Pediatric Dentistry, School of Dentistry of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil, ³Department of Orthodontics, University Medical Centre of Regensburg, Regensburg, Germany

Abstract

Introduction: This study aimed to evaluate if single nucleotide polymorphisms (SNPs) in runt-related transcription factor 2 (*RUNX2*) and bone morphogenetic protein 2 (*BMP2*) are associated with different craniofacial patterns. Furthermore, we also investigated if *RUNX2* and *BMP2* expression in the maxilla and mandible are differently expressed according to facial phenotypes and influenced by the SNPs in their encoding genes. Orthognathic patients were included. **Materials and Methods:** Lateral cephalometric radiographs were used to classify facial phenotypes based on Steiner's ANB and Ricketts' NBa-PtGn angles. Bone samples from 21 patients collected during orthognathic surgery were used for the gene expression assays. DNA from 129 patients was used for genotyping the SNPs rs59983488 and rs1200425 in *RUNX2* and rs235768 and rs1005464 in *BMP2*. The established alpha was 5%. **Results:** A statistically significant difference was observed in the relative BMP2 expression in the mandible between Class I and III participants (*P* = 0.042). Homozygous GG (rs59983488) had higher RUNX2 expression (*P* = 0.036) in the mandible. In maxilla, GG (rs1200425) had a higher BMP2 expression (*P* = 0.038). **Discussion:** In conclusion, BMP2 is expressed differently in the mandible of Class I and Class III participants. Genetic polymorphisms in *RUNX2* and *BMP2* are associated with their relative gene expression.

Keywords: Craniofacial morphology, facial type, gene expression, polymorphism, skeletal class

INTRODUCTION

Craniofacial growth and development is a complex process involving many molecular aspects.^[1,2] The growth process of the maxilla and other midfacial bones is associated with the growth of the mandible and the cranial base.^[3,4] Variations in craniofacial growth lead to different sagittal and vertical morphological patterns.^[5-7] Sagittal patterns are most frequently classified into skeletal malocclusion Class I, II, and III,^[8] whereas vertical patterns are differentiated into mesofacial, dolichofacial, and brachyfacial facial growth patterns.^[9]

Many molecular and genetic factors are responsible for triggering the growth process.^[1,2,4] Among them, runt-related transcription factor 2 (RUNX2) and bone morphogenetic

Access this article online		
Quick Response Code:	Website: www.amsjournal.com	
	DOI: 10.4103/ams.ams_40_21	

protein 2 (*BMP2*)^[2] should be highlighted due to their important role in the craniofacial development.

Departmento de Esto	ddress for correspondence: Dr. Rafaela Scariot, matologia, Faculdade de Odontologia, University la Prefeito Lothario Meissner, 632, Curitiba (PR), Brazil. E-mail: rafaela_scariot@yahoo.com.br
Received: 10-02-2021	Last Revised: 24-09-2021
Accepted: 09-11-2021	Published: 01-02-2022

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Olsson B, da Silva MJ, Lago C, Calixto RD, Ramazzotto LA, Barbosa Rebellato NL, *et al*. Single nucleotide polymorphisms in runt-related transcription factor 2 and bone morphogenetic protein 2 impact on their maxillary and mandibular gene expression in different craniofacial patterns - A comparative study. Ann Maxillofac Surg 2021;11:222-8.

RUNX2 is a gene that encodes a transcription factor essential for bone formation and skeletal morphogenesis. This protein plays a role in the regulation of factors involved in skeletal gene expression, such as the expression of bone sialoprotein, collagen type 1 α (*COL1A1*), and osteocalcin (*BGLAP2*).^[9]

BMP2 is a gene that encodes ligands of the transforming growth factor-beta superfamily of proteins.^[2,10] These ligands are responsible for bone and cartilage formation due to its role in osteoblast and chondroblast differentiation.^[9] BMP signaling pathway is associated with the fusion of facial patterns.^[2,11]

Single nucleotide polymorphisms (SNPs) have the potential to alter all steps of gene expression depending on their genomic location. When they are within transcriptional regulatory elements, SNPs can affect mRNA (messenger RNA) expression,^[12] impacting the phenotype. SNPs in many genes have been associated with different sagittal and vertical craniofacial patterns in humans,^[5-7,13] including SNPs in *RUNX2* and *BMP2*, which were associated with different maxillary and mandibular phenotypes.^[13]

Although many studies have been evaluating the association between SNPs in genes with different craniofacial patterns, the interplay among SNPs, gene expression and craniofacial pattern has not been explored yet. Therefore, in this study, we evaluated if SNPs in *RUNX2* (rs59983488 and rs1200425) and *BMP2* (rs235768 and rs1005464) are associated with different craniofacial patterns in patients presenting for orthognathic surgery. Furthermore, we also investigated if *RUNX2* and *BMP2* expression (mRNA) in the maxilla and mandible are differently expressed according to facial patterns and are influenced by the SNPs in their encoding genes. Thus, SNPs as well as the relative gene expression of *RUNX2* and *BMP2* in bone samples from the maxilla and mandible were explored in patients submitted to orthognathic surgery.

MATERIALS AND METHODS

Ethical considerations

This study was approved by the ethical committee of the Federal University of Parana (26502919.6.0000.0093). All procedures performed in the study were conducted in accordance with the ethics standards given in 1964 Declaration of Helsinki, as revised in 2013. All the participants provided written informed consent for the participation in the study.

Sample selection and study design

Patients with finalized orthodontic preparation were invited to participate consecutively during a 2-year period. This cross-sectional study followed three steps: (1) Gene expression analysis using maxillary and mandibular bone samples from 21 patients to explore if *RUNX2* and *BMP2* are differentially expressed according to craniofacial patterns; (2) Functional analysis to evaluate, if SNPs in *RUNX2* and *BMP2* are potentially involved in the expression variations of RUNX2 and BMP2 within the maxilla and mandible; (3) Genotyping analysis of DNA samples from 129 patients to evaluate, if SNPs in *RUNX2* and *BMP2* are associated with craniofacial patterns.

Adult patients referred to orthognathic surgery were included. Patients were invited to participate at universities and a private office (Curitiba, PR, Brazil). The oral and maxillofacial surgeon invited the patients to participate. Participants' systemic condition was classified according to the American Society of Anaesthesiologists (ASA) Physical Status Classification System. Syndromic patients and patients with ASA III or higher were excluded.

Cephalometric analysis

All patients presented a pretreatment digital lateral cephalometric radiograph, which was analyzed by a single expert surgeon. Radiographs were taken in the centric jaw relationship. Dolphin 2D[®] software (Dolphin Imaging software, Microsoft) was traced for the following angular measurements:

- Facial axis (Ricketts') (NBa-PtGn°): angle between Nasion-Basion (NaBa) and Pterygomaxillary fissure-Gnathion (PtGn) lines
- ANB° (Steiner) (ANB°): angle formed between A point-Nasion (AN) and Nasion-B point (NB) lines.

Patients were classified according to the ANB° as Class I (0°–4°), Class II (>4°) and Class III (<0°), and according to NBa-PtGn° as mesofacial (87°–93°), dolichofacial (<87°), or brachyfacial (>93°).

Sample collection for relative gene expression analysis of runt-related transcription factor 2 and bone morphogenetic protein 2

Bone samples (surgical waste) were collected from maxilla and/or mandible, depending on the surgical plan (i.e., mono-or-bimaxillary surgery). Maxillary samples were collected from any region in the area of the Le Fort I osteotomy (as long as they were interfering with maxillary adaptation) after the downfracture. In the mandible, samples were collected from the bilateral sagittal split osteotomy region. The samples were stored in tubes containing RNAlater solution and frozen immediately after surgery.

Relative gene expression analysis are described in the Supplementary Material and was previously reported by Olsson *et al.*^[14]

Briefly, the target genes RUNX2 (Hs00231692_m1) and BMP2 (Hs00154192_m1) and the reference genes ACTB (Hs01060665_g1) and GAPDH (Hs02758991_g1) were used. The 2- Δ Cycle Threshold method was used to determine the relative levels of mRNA expression.

Sample collection for genotyping analysis

Saliva samples were collected for DNA extraction following a previously described method.^[15] The SNPs described in Table 1 were blindly genotyped (described in the Supplementary Material) as previously reported.^[16] An internal consistency of 100% was obtained by randomly repeating 10% of all samples.

Statistical analysis

Statistical analysis was performed using the Prism GraphPad8.2 package (GraphPad Software, Inc., San Diego, CA-USA). Data normality was assessed with the Kolmogorov – Smirnov and Shapiro – Wilk tests.

One-way analysis of variance or *t*-test was used to compare the mean and standard deviation (SD) relative gene expression. The Chi-square test was used to compare the SNPs according to the phenotypes. A correlation of gene expressions was tested using the Spearman's correlation test. An established alpha of 0.05 was adopted.

RESULTS

A total of 129 individuals were included: 86 (66.7%) females and 43 (33.3%) males. Thirty-two (24.8%) were Class I, 24 (18.6%) were Class II, and 73 (56.6%) were Class III. Regarding NBa-PtGn°, 70 (54.3%) were brachyfacial, 37 (28.7%) mesofacial, and 22 (17.1%) dolichofacial.

Bone samples from 14 mandibles and 17 maxillas from 21 individuals (8 males and 13 females) were used in this analysis. Regarding skeletal malocclusion, 7 participants were Class I,

4 were Class II, and 10 were Class III. Eight participants were mesofacial, 7 dolichofacial, and 6 brachyfacial.

Figure 1 shows the RUNX2 and BMP2 expression in the mandible and maxilla (P = 0.783).

Figure 2 demonstrated the relative RUNX2 and BMP2 expression according to the skeletal malocclusions. A statistically significant difference was observed for BMP2 expression in mandibular bone from Class I and III participants (P = 0.042).



Figure 1: Relative mRNA expression according to each dental arch (mandible and maxilla). (a) Mean and standard deviation of runt-related transcription factor 2. (b) Mean and standard deviation of bone morphogenetic protein 2

Table 1: Characteristics of the single nucleotide polymorphisms studied					
Gene	Chromosome	Reference sequence	Position/function	Base change (context sequence)	Global MAF
RUNX2	6	rs59983488	Intron variant	GGG[G/T] AGT	0.1787
		rs1200425	Intron variant	TTT[G/A] GAA	0.4297
BMP2	20	rs235768	Missense R (Arg)>S (Ser)	CAG[A/T] CTT	0.2332
		rs1005464	Intron variant	GCC[A/G] GCC	0.2232

Table 2: Mean mRNA levels in the mandible a	ind maxilla according to single nucleotide	e polymorphisms genotypes

Arch	SNPs	Genotypes	and mean (SD) relative mRNA	A expression	P §
Mandible	RUNX2				
	rs59983488	GG	GT	TT	
		1.58 (1.02)	0.31 (0.27)	-	0.036*
	rs1200425	AA	AG	GG	
		1.30 (1.52)	0.95 (0.63)	1.28 (0.71)	0.874
	BMP2				
	rs235768	AA	AT	TT	
		10.7 (4.50)	12.71 (15.98)	28.21 (19.75)	0.230
	rs1005464	AA	AG	GG	
		3.73 (-)	21.36 (23.81)	17.60 (15.03)	0.686
Maxilla	RUNX2				
	rs59983488	GG	GT	TT	
		1.74 (1.50)	1.23 (0.61)	-	-
	rs1200425	AA	AG	GG	
		0.96 (0.56)	1.38 (0.81)	3.17 (2.15)	0.038*
	BMP2				
	rs235768	AA	AT	TT	
		13.98 (17.94)	19.68 (16.84)	13.34 (17.07)	0.789
	rs1005464	AA	AG	GG	
		40.96 (-)	15.90 (15.83)	13.37 (14.86)	0.258

[§]ANOVA or *t*-test were used, *Means statistically significant difference. SNPs: Single nucleotide polymorphisms

Olsson, et al.: SNPs impact on gene expression in different craniofacial patterns



Figure 2: Relative mRNA expression according to the skeletal malocclusions. (a) Runt-related transcription factor 2 expression in the mandible. (b) Runt-related transcription factor 2 expression in the maxilla. (c) Bone morphogenetic protein 2 expression in the mandible. (d) Bone morphogenetic protein 2 expression in the maxilla



Figure 3: Relative mRNA expression according to the facial growth patterns. (a) Runt-related transcription factor 2 expression in the mandible. (b) Runt-related transcription factor 2 expression in the maxilla. (c) Bone morphogenetic protein 2 expression in the mandible. (d) Bone morphogenetic protein 2 expression in the maxilla

Figure 3 demonstrated the relative RUNX2 and BMP2 expression according to the facial growth patterns (P > 0.05). Mean and SD for each comparison are presented in Supplementary Table 1.

There was no correlation between *RUNX2* and *BMP2* expression neither in the mandible (r = 0.227; P = 0.379) nor in the maxilla (r = 0.389; P = 0.574).

In *RUNX2*, the genotype distribution in rs59983488 was: GG = 14, GT = 6 and TT = 0; while in rs1200425 was: AA = 6, AG = 10, and GG = 4. In *BMP2*, in the rs235768 was: AA = 5, AT = 8 and TT = 6, while in rs1005464 was: AA = 1, AG = 6 and GG = 13.

Table 2 demonstrates the *RUNX2* and *BMP2* expression according to the genotypes. A statistical significance was observed in rs59983488 (P = 0.036) and in rs1200425 (GG vs. GA, P = 0.038).

Due to associations and borderline associations observed in the first steps of this study, a genotyping analysis was performed in the total sample of 129 individuals. Table 3 shows genotype frequencies according to the phenotypes. No association was observed (P > 0.05).

DISCUSSION

In the past years, there was an increase in SNP-phenotype^[5-7] and genome-wide association studies (GWAS),^[16,17] in which many genes/SNPs were linked to some craniofacial phenotypes, including $RUNX2^{[16-18]}$ and BMP2.^[19-21] However, the understanding of the functional impact of SNPs on gene expression within craniofacial tissue is still largely unexplored. Here, we provide novel findings of the impact of RUNX2 and BMP2 SNPs on their maxillary and mandibular gene expression in different craniofacial patterns.

In our study, BMP2 was differentially expressed in the mandible according to the skeletal malocclusion. Mandibular bone samples from skeletal Class III patients showed a lower BMP2 expression, when compared to skeletal Class I. Interestingly, SNPs in *BMP2* are associated with mandibular retrognathism.^[13] BMP2 is an essential regulator of osteogenesis, which directly regulates target gene expression^[22] crucial for proper development. In osteoblasts, the target genes of BMP2 encode many transcription factors, including RUNX2,^[23] known as highly important for the determination of craniofacial pattern.

RUNX2 function in osteoblast differentiation is affected by many regulatory genes.^[24] RUNX2 also interacts with several coregulatory transcription factors, forming complexes that regulate the transcription of many bone-related factors in osteoblasts.^[24] Mutations in RUNX2 and expression levels of RUNX2 may be involved in the development of several craniofacial defects.^[25] SNPs in RUNXs are involved in different craniofacial patterns.^[13] Although our results of RUNX2 expression in the bone were not statistically different across skeletal patterns, the gene expression distribution conforms to previous evidence in the literature suggesting that RUNX2 is worth further investigation. Therefore, we performed a functional analysis in our study and found that the GG genotype of rs59983488 was associated with a higher expression of RUNX2 in the mandible.

Table 3: Genotype frequencies according to the respective craniofacial pattern

•	icial patte				
Phenotype	Ge	notypes, <i>n</i> (%)	Р	
	RUN	RUNX2 rs59983488			
	GG	GT	TT		
Skeletal malocclusion					
Class I	21 (72.4)	8 (27.6)	0	Reference	
Class II	12 (57.1)	7 (33.4)	2 (9.5)	0.189	
Class III	41 (63.1)	24 (36.9)	0	-	
Growth pattern					
Mesofacial	16 (55.2)	13 (44.8)	0	Reference	
Dolichofacial	14 (66.7)	5 (23.8)	2 (9.5)	0.104	
Brachyfacial	44 (67.8)	21 (33.2)	0	0.243	
Phenotype		notypes, <i>n</i> (%)	Р	
,,		NX2 rs1200			
	AA	AG	GG		
<u>Clashed and a share and</u>	~~~	Au	uu		
Skeletal malocclusion Class I	0 (75 0)	14 (45 2)	0 (20.0)	Deferrer	
	8 (25.8)	14 (45.2)	9 (29.0)	Reference	
Class II	6 (28.6)	8 (38.1)	7 (33.3)	0.878	
Class III	13 (18.5)	34 (48.6)	23 (32.9)	0.707	
Growth pattern	- (*** 0)				
Mesofacial	7 (20.6)	14 (41.2)	13 (38.2)	Reference	
Dolichofacial	8 (38.1)	8 (38.1)	5 (23.8)	0.314	
Brachyfacial	12 (17.9)	34 (50.7)	21 (31.1)	0.657	
Phenotype	Ge	notypes, <i>n</i> (%)	Р	
	BI	<i>NP2</i> rs2357	68		
		AT	TT		
	AA				
Skeletal malocclusion	AA				
Skeletal malocclusion Class I	AA 4 (12.9)	14 (45.2)	13 (41.9)	Reference	
		14 (45.2) 8 (38.1)	13 (41.9) 11 (52.4)	Reference 0.752	
Class I	4 (12.9)		. ,		
Class I Class II	4 (12.9) 2 (9.5)	8 (38.1)	11 (52.4)	0.752	
Class I Class II Class III	4 (12.9) 2 (9.5)	8 (38.1)	11 (52.4)	0.752 0.987	
Class I Class II Class III Growth pattern	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1)	8 (38.1) 30 (44.8) 13 (39.4)	11 (52.4) 29 (43.3) 16 (48.5)	0.752 0.987	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8)	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1)	0.752 0.987 Reference	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8)	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5)	0.752 0.987 Reference 0.476	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %)	0.752 0.987 Reference 0.476 0.542	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, <i>n</i> (11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %)	0.752 0.987 Reference 0.476 0.542	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge BM	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, n (1/2 rs10054	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %) 164	0.752 0.987 Reference 0.476 0.542	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial Phenotype	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge BM AA	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, <i>n</i> (<i>IP2</i> rs10054 AG	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %) 164 GG	0.752 0.987 Reference 0.476 0.542 P	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial Phenotype Skeletal malocclusion Class I	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge BM AA 2 (6.4)	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, <i>n</i> (<i>IP2</i> rs10054 AG 11 (35.5)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %) 164 GG 18 (58.1)	0.752 0.987 Reference 0.476 0.542 P Reference	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial Phenotype Skeletal malocclusion Class I Class II	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge BM AA 2 (6.4) 3 (14.3)	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, n (//2 rs10054 AG 11 (35.5) 5 (23.8)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %) H64 GG 18 (58.1) 13 (61.9)	0.752 0.987 Reference 0.476 0.542 P Reference 0.500	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial Phenotype Skeletal malocclusion Class I Class II Class III	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge BM AA 2 (6.4)	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, <i>n</i> (<i>IP2</i> rs10054 AG 11 (35.5)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %) 164 GG 18 (58.1)	0.752 0.987 Reference 0.476 0.542 P Reference	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial Phenotype Skeletal malocclusion Class I Class II Class III Growth pattern	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge Bin AA 2 (6.4) 3 (14.3) 3 (4.2)	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, n (7P2 rs10054 AG 11 (35.5) 5 (23.8) 23 (32.9)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %) 164 GG 18 (58.1) 13 (61.9) 44 (62.9)	0.752 0.987 Reference 0.476 0.542 P Reference 0.500 0.848	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial Phenotype Skeletal malocclusion Class I Class II Class III Growth pattern Mesofacial	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge BN AA 2 (6.4) 3 (14.3) 3 (4.2) 2 (6.1)	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, n (7P2 rs10054 AG 11 (35.5) 5 (23.8) 23 (32.9) 11 (33.3)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %) [64 [64] [64] [66] [18 (58.1) 13 (61.9) 44 (62.9) 20 (60.6)	0.752 0.987 Reference 0.476 0.542 P Reference 0.500 0.848 Reference	
Class I Class II Class III Growth pattern Mesofacial Dolichofacial Brachyfacial Phenotype Skeletal malocclusion Class I Class II Class III Growth pattern	4 (12.9) 2 (9.5) 8 (11.9) 4 (12.1) 1 (4.8) 9 (13.8) Ge Bin AA 2 (6.4) 3 (14.3) 3 (4.2)	8 (38.1) 30 (44.8) 13 (39.4) 8 (38.1) 31 (47.7) notypes, n (7P2 rs10054 AG 11 (35.5) 5 (23.8) 23 (32.9)	11 (52.4) 29 (43.3) 16 (48.5) 12 (57.1) 25 (38.5) %) 164 GG 18 (58.1) 13 (61.9) 44 (62.9)	0.752 0.987 Reference 0.476 0.542 P Reference 0.500	

It is important to highlight that although our study did not demonstrate an association between the SNPs in *BMP2* and *RUNX2* and the craniofacial pattern, it does not mean that they are not involved in craniofacial phenotypes. Genetic variants in *RUNX2* produce a deficient *RUNX2* protein leading to cleidocranial dysostosis,^[26] which affects dental arches.^[27] Furthermore, disruptions in BMP signaling cause Treacher-Collins syndrome, which clinically presents remarkable craniofacial alterations.^[2] Adhikari et al., (2016) performed a GWAS for facial features (using photographs) in Latin Americans and observed that SNPs in RUNX2 affected nose morphology. Recently, Küchler et al. (2021) performed a SNP-phenotype association study in Brazilians, also using cephalometrics to determine the phenotypes, and observed that SNPs in RUNX2 and BMP2 were involved in a variety of craniofacial phenotypes, including skeletal Class II, mandibular retrognathism, mandibular protrusion, and dolichofacial phenotype.^[13] It is possible that our sample led to a type II error in the genotype analysis, as some phenotypic groups presented a small sample size.

In the general population, skeletal Class I is more prevalent than Class II, followed by Class III.^[28,29] Our sample was mainly composed by Class III individuals due to the fact that only patients seeking orthognathic surgery were included.^[30] This might also explain the difference between the results observed here and in a previous study^[13] evaluating orthodontic patients, in which SNPs in *RUNX2* and *BMP2* were associated with different craniofacial patterns.

CONCLUSION

BMP2 is expressed differently in the mandible of Class I and Class III participants. SNPs in *RUNX2* and *BMP2* are involved with their relative gene expression in the mandible and maxilla, respectively.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

- Nie X. Cranial base in craniofacial development: Developmental features, influence on facial growth, anomaly, and molecular basis. Acta Odontol Scand 2005;63:127-35.
- Graf D, Malik Z, Hayano S, Mishina Y. Common mechanisms in development and disease: BMP signaling in craniofacial development. Cytokine Growth Factor Rev 2016;27:129-39.
- Björk A. Facial growth in man, studied with the aid of metallic implants. Acta Odontol Scand 1995;13:9-34.
- Manjusha KK, Jyothindrakumar K, Nishad A, Manoj KM. Growth and development of dentofacial complex influenced by genetic and environmental

factors using monozygotic twins. J Contemp Dent Pract 2017;18:754-8.

- 5. Küchler EC, Nascimento MA, Matsumoto MA, Romano FL, da Silva RA, Ayumi Omori M, *et al.* Genetic polymorphism in RANK is associated with mandibular size. J Orthod 2018;45:157-62.
- Cunha A, Nelson-Filho P, Marañón-Vásquez GA, Ramos AG, Dantas B, Sebastiani AM, *et al.* Genetic variants in ACTN3 and MYO1H are associated with sagittal and vertical craniofacial skeletal patterns. Arch Oral Biol 2019;97:85-90.
- Cavalcante RC, Bergamaschi IP, Sebastiani AM, Meger M, Signorini L, Costa DJ, *et al.* Association between facial measurements and polymorphisms in human epidermal growth factor and transforming growth factor β1. Br J Oral Maxillofac Surg 2020;58:214-9.
- 8. Angle E. Classification of malocclusion. Dent Cosm 1899;41:248-64.
- Yoo SH, Kim JG, Kim BS, Lee J, Pi SH, Lim HD, et al. BST2 mediates osteoblast differentiation via the BMP2 signaling pathway in human alveolar-derived bone marrow stromal cells. PLoS One 2016;11:e0158481.
- Jani P, Liu C, Zhang H, Younes K, Benson MD, Qin C. The role of bone morphogenetic proteins 2 and 4 in mouse dentinogenesis. Arch Oral Biol 2018;90:33-9.
- Bennett JH, Hunt P, Thorogood P. Bone morphogenetic protein-2 and -4 expression during murine orofacial development. Arch Oral Biol 1995;40:847-54.
- Robert F, Pelletier J. Exploring the impact of single-nucleotide polymorphisms on translation. Front Genet 2018;9:507.
- Küchler EC, Reis CL, Carelli J, Scariot R, Nelson-Filho P, Coletta RD, et al. Potential interactions among single nucleotide polymorphisms in bone- and cartilage-related genes in skeletal malocclusions. Orthod Craniofac Res 2021;24:277-87.
- Olsson B, Calixto RD, da Silva Machado NC, Meger MN, Paula-Silva FW, Rebellato NL, *et al.* MSX1 is differentially expressed in the deepest impacted maxillary third molars. Br J Oral Maxillofac Surg 2020;58:789-94.
- Küchler EC, Tannure PN, Falagan-Lotsch P, Lopes TS, Granjeiro JM, Amorim LM. Buccal cells DNA extraction to obtain high quality human genomic DNA suitable for polymorphism genotyping by PCR-RFLP and real-time PCR. J Appl Oral Sci 2012;20:467-71.
- Claes P, Roosenboom J, White JD, Swigut T, Sero D, Li J, *et al.* Genome-wide mapping of global-to-local genetic effects on human facial shape. Nat Genet 2018;50:414-23.
- Adhikari K, Fuentes-Guajardo M, Quinto-Sánchez M, Mendoza-Revilla J, Camilo Chacón-Duque J, Acuña-Alonzo V, et al. A genome-wide association scan implicates DCHS2, RUNX2, GLI3, PAX1 and EDAR in human facial variation. Nat Commun 2016;7:11616.
- Wu T, Fallin MD, Shi M, Ruczinski I, Liang KY, Hetmanski JB, et al. Evidence of gene-environment interaction for the RUNX2 gene and environmental tobacco smoke in controlling the risk of cleft lip with/without cleft palate. Birth Defects Res A Clin Mol Teratol 2012;94:76-83.
- Mu Y, Xu Z, Contreras CI, McDaniel JS, Donly KJ, Chen S. Phenotype characterization and sequence analysis of BMP2 and BMP4 variants in two Mexican families with oligodontia. Genet Mol Res 2012;11:4110-20.
- 20. Lu Y, Qian Y, Zhang J, Gong M, Wang Y, Gu N, *et al.* Genetic variants of BMP2 and their association with the risk of non-syndromic tooth agenesis. PLoS One 2016;11:e0158273.
- Saket M, Saliminejad K, Kamali K, Moghadam FA, Anvar NE, Khorram Khorshid HR. BMP2 and BMP4 variations and risk of non-syndromic cleft lip and palate. Arch Oral Biol 2016;72:134-7.
- Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005;19:2783-810.
- Nakashima K, de Crombrugghe B. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet 2003;19:458-66.
- 24. Kim BS, Kim HJ, Kim JS, You YO, Zadeh H, Shin HI, *et al.* IFITM1 increases osteogenesis through Run×2 in human alveolar-derived bone marrow stromal cells. Bone 2012;51:506-14.
- Eswarakumar VP, Horowitz MC, Locklin R, Morriss-Kay GM, Lonai P. A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis. Proc Natl Acad Sci U S A 2004;101:12555-60.

- Gao X, Li K, Fan Y, Sun Y, Luo X, Wang L, *et al.* Identification of RUNX2 variants associated with cleidocranial dysplasia. Hereditas 2019;156:31.
- Yamashiro T, Aberg T, Levanon D, Groner Y, Thesleff I. Expression of Runx1, -2 and -3 during tooth, palate and craniofacial bone development. Mech Dev 2002;119 Suppl 1:S107-10.
- Alhammadi MS, Halboub E, Fayed MS, Labib A, El-Saaidi C. Global distribution of malocelusion traits: A systematic review. Dental Press J

Orthod 2018;23:40.e1- 40.e10.

- Al Jadidi L, Sabrish S, Shivamurthy PG, Senguttuvan V. The prevalence of malocclusion and orthodontic treatment need in Omani adolescent population. J Orthod Sci 2018;7:21.
- Gabardo M, Zielak J, Tórtora G, Gerber J, Meger M, Rebellato N, *et al.* Impact of orthognathic surgery on quality of life: Predisposing clinical and genetic factors. J Craniomaxillofac Surg 2019;47:1285-91.

Supplementary Material

Supplementary Table 1: Mean and standard deviation for each analysis

Gene	Arch	Mean (SD)	Р		
	Gene expression in maxilla and mandible [data from Figure 1]				
Runx2	Mandible	1.14 (0.99)	0.346		
	Maxilla	1.55 (1.26)			
BMP2	Mandible	16.57 (16.93)	0.783		
	Maxilla	14.95 (15.58)			
Gene	Arch	Mean (SD)	Р		
		the maxilla and mandible locclusion [data from Fig			
RUNX2	Mandible				
	Class I	0.89 (0.79)	>0.05		
	Class II	1.52 (1.42)			
	Class III	1.12 (1.00)			
	Maxilla				
	Class I	1.79 (1.94)	>0.05		
	Class II	1.95 (0.49)			
	Class III	1.21 (0.78)			
BMP2	Mandible				
	Class I	28.59 (20.37)	>0.05		
	Class II	12.09 (11.22)			
	Class III	6.79 (6.12)			
	Maxilla				
	Class I	20.57 (14.31)**	0.042		
	Class II	25.63 (21.55)			
	Class III	5.56 (9.48)*			
Gene	Arch	Mean (SD)	Р		
	Gene expression in	the maxilla and mandible	e according		
	to the facial	pattern [data from Figur			
RUNX2	Mandible				
	Mesofacial	1.08 (0.71)	>0.05		
	Dolichofacial	1.01 (1.24)			
	Brachyfacial	1.38 (1.12)			
	Maxilla				
	Mesofacial	1.60 (1.88)	>0.05		
	Dolichofacial	1.32 (0.71)			
	Brachyfacial	1.97 (0.36)			
BMP2	Mandible				
	Mesofacial	23.06 (21.93)	>0.05		
	Dolichofacial	18.10 (16.23)			
	Brachyfacial	6.16 (6.26)			
	Maxilla				
	Mesofacial	10.78 (13.61)	>0.05		
	Dolichofacial	23.68 (16.49)			
	Brachyfacial	3.42 (2.07)			

SD: Standard deviation; * Means statistically significant difference

PCR METHOD

Relative gene expression analysis of runt-related transcription factor 2 and bone morphogenetic protein 2 For relative gene expression analysis, mirVana miRNA isolation kit (Ambion/Life TechnologiesTM) was used to perform RNA isolation. The spectrophotometer NanoDropTMOne (Thermo Fisher Scientific, Massachusetts, USA) was used to assess purity and RNA concentration. The High-Capacity[®] cDNA Reverse Transcription Kit (Applied Bio-systems, Foster City, CA, USA) was used. For the reaction, 400 ng of RNA, 0.8 µL of dNTP Mix ×25, 2.0µL of RT Buffer ×10, 2 µL of ×10 RT Random Primers and 1.0µL of MultiScribe[®] enzyme (50 U/µL) were used in a final volume of 20µL.

Both the gene expression and the reverse transcription reaction were run in a StepOnePlus Real-Time Polymerase Chain Reaction System (Applied Biosystems). The target genes *runt-related transcription factor 2* (Hs00231692_m1) and *bone morphogenetic protein 2* (Hs00154192_m1) TaqManTM Gene Expression Assay primers and probes were used. As reference genes we used *ACTB* (Hs01060665_g1) and *GAPDH* (Hs02758991_g1). Amplification was performed under the following conditions: 95°C for 2 min, followed by 40 cycles of 95°C for 1s and 60°C for 20s. The 2- Δ Cycle Threshold method was used to determine the relative levels of mRNA expression.

Genotyping analysis

The spectrophotometer NanoDropTMOne (Thermo Fisher Scientific, Massachusetts, USA) was used to assess purity and DNA concentration. The SNPs were blindly investigated using TaqManTM technology (Applied Bio-systems, Foster City, CA, USA) in the same real-time PCR system described above, following the reaction: 4 ng DNA/reaction, 1.5µL Taqman PCR master mix and 0.075µL SNP assay (Applied Biosystems, Foster City, CA, USA) in a total volume of 3 µL. The thermal cycle was 10 min hold-cycle at 95°C and 40 amplification cycles of 15 s at 92°C and 1 min at 60°C. An internal consistency of 100% was obtained by randomly repeating 10% of all samples.